Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Wilms Tumor 1Multiple Myeloma 1Hematologic Neoplasms 1

Interventions

Vincristine 16Cyclophosphamide 16Filgrastim 13Etoposide 12Doxorubicin 12Radiotherapy 11Carboplatin 10X-Rays 9Dactinomycin 9Specimen Handling 8Phantoms, Imaging 8Magnetic Resonance Spectroscopy 8Granulocyte Colony-Stimulating Factor 8Temozolomide 6Melphalan 6Ifosfamide 6Topotecan 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Irinotecan 5Busulfan 5Biopsy 5sargramostim 4Stem Cell Transplantation 4Thiotepa 3Radiation 3Nivolumab 3Mesna 3Itraconazole 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Wilms Tumor × Immunomodulating Agents × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡